Pregled bibliografske jedinice broj: 1258020
The role of pharmacogenetics as possible risk factor for rivaroxaban - associated bleeding
The role of pharmacogenetics as possible risk factor for rivaroxaban - associated bleeding // Pharmaca, 52 (2022), Suppl 2
Opatija, Hrvatska, 2022. str. 141-141 (poster, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 1258020 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The role of pharmacogenetics as possible risk factor
for rivaroxaban - associated bleeding
Autori
Šimičević, Livija ; Slišković, Ana Marija ; Vrkić Kirhmajer, Majda ; Ganoci, Lana ; Holik, Hrvoje ; Samardžić, Jure ; Božina, Tamara
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Pharmaca, 52 (2022), Suppl 2
/ - , 2022, 141-141
Skup
10. hrvatski kongres farmakologije ; 1. hrvatski kongres kliničke farmakologije s međunarodnim sudjelovanjem = 10th Croatian Congress of Pharmacology ; 1st Croatian Congress of Clinical Pharmacology and Therapeutics with International Participation
Mjesto i datum
Opatija, Hrvatska, 22.09.2022. - 25.09.2022
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
adverse events ; pharmacogenetics ; rivaroxaban ; risk factors
Sažetak
Introduction: Rivaroxaban has large interindividual trough concentration variability affecting its efficacy and safety, especially bleeding events. This variability could be associated with age, liver and kidney function, concomitant illness and therapy, and pharmacogenetic predisposition. Rivaroxaban is a substrate of ABCB1 and ABCG2 transporters, and CYP2J2, CYP3A4/5 enzymes. The polymorphisms of these genes may affect the pharmacokinetics of rivaroxaban and its safety profile. Aim of the study is to evaluate role of pharmacogenetics as possible risk factor for rivaroxaban-associated bleeding in patients treated for cardiovascular diseases. Patients and Methods: Presented data are part of the larger prospective nested case-control study “Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction”. Clinical and laboratory data were collected. Pharmacogenetic analyses were performed using specific TaqMan® DME and SNP Assays on 7500 Real- Time PCR System for genotyping of CYP3A4*1B*22, CYP3A5*3, CYP2J2*7, c.1331- 2201T>C, ABCB1 (c.1236C>T, c.2482-2236G>A, c.2677G>T/A, c.3435C>T) and ABCG2 (c.421C>A) variants. For drug-drug interactions (DDI), The Lexicomp® Clinical Decision Support System was applied. Results: Sixteen patients (median age 73 years, range 61-80) with rivaroxaban-associated bleeding: gastrointestinal (N=9), epistaxis (N=5), haematuria (N=1) and gynaecological (N=1) were analysed. In 9/16 DDI with increased bleeding risk were found. Two patients had eGFR>90, while six patients had eGFR<60. Only three patients who experienced bleeding did not have any of investigated risk factors including gene variants. Conclusions: Our data suggest a possible role of pharmacogenetic and clinical factors and their interactions in predicting bleeding on rivaroxaban treatment. These findings indicate the need for further comprehensive research.
Izvorni jezik
Engleski
Znanstvena područja
Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti, Farmacija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Projekti:
HRZZ-UIP-2020-02-8189 - Uloga farmakogenomike u predviđanju nuspojava kardiovaskularnih lijekova (PGx-CardioDrug) (Božina, Tamara, HRZZ - 2020-02) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Opća bolnica "Dr. Josip Benčević",
Klinički bolnički centar Zagreb
Profili:
Jure Samardžić
(autor)
Lana Ganoci
(autor)
Ana Marija Slišković
(autor)
Tamara Božina
(autor)
Majda Vrkić Kirhmajer
(autor)
Hrvoje Holik
(autor)
LIVIJA ŠIMIČEVIĆ
(autor)